QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Positive aspects include a significant increase in adjusted EBITDA and EPS, and successful cost-saving measures. However, negative factors such as a decrease in gross profit margin, negative free cash flow, and unclear timelines for new product developments temper the outlook. The Q&A highlights competitive wins and strategic geographic expansion, but also exposes risks like lower Q4 margins and technical challenges. Given the market cap, these mixed factors suggest a neutral stock price movement within the next two weeks.
Key Financial Performance
Organic Sales Growth 5%, excluding COVID sales and the U.S. donor screening business. Growth driven by labs, immunohematology, and point-of-care businesses.
Adjusted EBITDA Margin 25%, a 180 basis point improvement year-over-year. Improvement due to cost-saving initiatives delivering over $140 million in savings.
Labs Business Revenue 4% growth. Driven by demand for VITROS immunoassay and clinical chemistry platforms, stable customer renewal rates, and new business wins.
Immunohematology Business Revenue 5% growth. Reflecting strong demand from blood banks and hospitals, expansion of automated testing solutions, and strengthening position in key geographies.
Point-of-Care Business Revenue 7% growth in Triage product line. Supported by value proposition, momentum in cardiac and BMP testing, and international market contributions.
Other Cardiac Revenue Increased by $8 million compared to the prior year period.
Respiratory Revenue Declined 63% in COVID revenue and 8% in flu revenue year-over-year. Decline attributed to timing and reduced COVID-related demand.
North America Revenue Down 12% in total, but up 5% year-over-year excluding respiratory revenue and U.S. donor screening exit.
Latin America Revenue 21% overall growth and 22% growth in labs. Driven by historical underpenetration and strong performance.
Japan, Asia Pacific, and China Revenue Approximately 5% growth in each region.
Europe, Middle East, and Africa Revenue 3% growth. EBITDA margins increased by over 700 basis points year-to-date due to cost discipline and focus on profitable growth.
Adjusted Gross Profit Margin 48.7%, a 50 basis point decrease year-over-year. Decrease due to tariff impacts offset by cost mitigations.
Non-GAAP Operating Expenses $217 million, a 7% decrease year-over-year. Decrease due to ongoing cost-saving actions.
Adjusted EBITDA $177 million, a 13% increase year-to-date compared to the prior year period. Reflects cost savings and margin expansion.
Adjusted Diluted EPS $0.80 in Q3 and $1.66 year-to-date, a 36% growth year-over-year. Growth driven by cost savings initiatives.
Adjusted Free Cash Flow Negative $50 million in Q3. Impacted by timing of accounts receivable collections and accounts payable disbursements due to ERP system conversion.
Net Debt to Adjusted EBITDA Ratio 4.4x. Slightly higher due to ERP system conversion impacts on Q3 cash flow.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VITROS high-sensitivity troponin assay: FDA clearance achieved; enhances cardiac panel performance with higher sensitivity and precision, enabling earlier heart attack detection and reducing unnecessary hospital admissions.
International market growth: Latin America grew 21%, Japan, Asia Pacific, and China grew approximately 5%, and Europe, Middle East, and Africa grew 3%. Growth driven by historical underpenetration and strategic focus on profitable growth.
Cost savings initiatives: Achieved over $140 million in cost savings, contributing to adjusted EBITDA margin expansion to 25%.
Manufacturing and supply chain optimization: Efforts to reduce procurement costs, optimize supply chain, and consolidate manufacturing footprint are ongoing.
ERP system conversion: Integration costs decreased, with significant cost reductions expected in 2026.
LEX Diagnostics acquisition: Ongoing FDA review for 510(k) and CLIA waiver submission; clearance anticipated by late 2025 or early 2026.
Discontinuation of Savanna platform development: Decision to discontinue development, resulting in $11 million in related charges.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
COVID and respiratory revenue decline: Respiratory revenue declined due to a 63% drop in COVID revenue and an 8% decrease in flu revenue year-over-year. This impacted North America revenue, which was down 12% overall.
Tariff impacts: Tariffs have negatively affected gross profit margins, with a 50 basis point year-over-year decrease in Q3 gross profit margin. The company is working on cost mitigations but continues to face challenges.
Legal and restructuring expenses: The company incurred $9 million in legal expenses related to a long-running COVID supplier dispute and $40 million in restructuring and integration charges, including $11 million for discontinuing the Savanna platform.
ERP system conversion challenges: The ERP system conversion caused temporary cash flow disruptions, including delayed accounts receivable collections and accelerated accounts payable disbursements, leading to a negative $50 million adjusted free cash flow in Q3.
Goodwill impairment: A $701 million goodwill impairment charge was recorded in Q3, leaving no goodwill on the balance sheet, which could impact investor confidence.
Debt and leverage concerns: Net debt to adjusted EBITDA ratio was 4.4x, slightly higher than anticipated due to ERP-related cash flow impacts. The company aims to reduce this to 2.5-3.5x but remains above target.
Donor screening business exit: The wind-down of the U.S. donor screening business contributed to a 4% year-over-year decrease in total reported revenue for Q3.
Regulatory delays for LEX Diagnostics: FDA clearance for LEX Diagnostics' 510(k) and CLIA waiver submission is delayed, now expected by late 2025 or early 2026, potentially impacting future growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Full year 2025 total reported revenue is expected to be between $2.68 billion and $2.74 billion, with a neutral FX impact.
COVID Revenue: Year-to-date COVID revenue was $60 million, and full-year expectations are between $70 million and $100 million, reflecting endemic levels.
Adjusted EBITDA Guidance: Full year 2025 adjusted EBITDA is expected to range between $585 million and $605 million, with an adjusted EBITDA margin of 22%, representing a 250 basis point improvement versus the prior year.
Cost Savings: Incremental cost savings in the range of $30 million to $40 million are expected in 2025, primarily related to indirect procurement efforts, in addition to tariff-related offsets.
Interest Expense: Full year interest expense is expected to total $177 million, reflecting a roughly 100 basis point increase in the weighted average interest rate and additional amortization of deferred financing fees.
Effective Tax Rate: The effective tax rate for the full year is expected to rise by roughly 1 percentage point to 25%, due to tariff mitigation measures shifting income across geographies.
Adjusted Diluted EPS: Full year 2025 adjusted diluted EPS is expected to be between $2.00 and $2.15, reflecting higher interest expense and taxes.
Respiratory Season Timing: The company expects a typical respiratory season with timing consistent with pre-pandemic patterns, occurring later in Q4 and into Q1 of the following year.
FDA Clearance for LEX Diagnostics: FDA clearance for LEX Diagnostics is anticipated by late 2025 or early 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details about the competitive wins, particularly in the labs segment and the impact of the new assay on VITROS?
A:The competitive wins are evenly distributed across geographies, with significant wins in North America, Latin America, and EMEA. The focus is on profitable wins rather than winning at all costs. The new high-sensitivity troponin assay strengthens the cardiac panel and is expected to be a long-term competitive factor, though it will not significantly impact short-term growth rates. Orders are expected later this year with shipping as soon as possible.
Q:Are you seeing any impact from VBP or DRG dynamics in China, and what is the outlook for growth in the region?
A:The company has adjusted its guidance to mid-single-digit growth due to competitive dynamics and policies like VBP and debundling. The impact has been less severe compared to others due to the high use of instruments in stat labs. The new procurement policy in China is being addressed by maintaining compliance with localization regulations.
Q:Why is the Q4 implied margin expected to be sequentially lower compared to Q3?
A:Margins in Q4 are expected to be slightly lower due to higher instrument revenue, which has lower margins compared to reagents and consumables, and higher incentive compensation expenses typical for Q4.
Q:What is the performance of instruments in Q3, and is there a timeline for the next-generation instrument?
A:Q3 instrument revenue was down by $5 million year-over-year due to higher contract extensions with existing customers, which is positive for margin mix. The next-generation instrument is in early concept development, and no timeline is available yet.
Q:Can you provide an update on the Sofia franchise and the durability of the ABC test?
A:The Sofia installed base is stable and expanding, with steady performance in flu combo test sales over the last two years. The company expects another solid respiratory season.
Q:What is the update on the LEX FDA submission and its impact on margins?
A:The FDA dialogue is constructive, with approval expected late this year or early 2026. LEX will have a limited rollout initially and a more extensive rollout in the second half of 2026. It is expected to have a dilutive impact on margins initially, with accretive impact not expected until 2027 or 2028.
Q:How should the U.S. donor screening business be modeled for next year, and what is the margin outlook?
A:The U.S. donor screening business is expected to wind down completely by mid-2026, removing a top-line headwind. Once stranded costs are removed, there will be a 50 basis point margin accretion by late 2026 or early 2027.
Q:What is the status of integrated analyzers in the lab business, and what is the long-term growth opportunity?
A:Integrated analyzers make up 30-40% of the installed base, with significant growth potential as competitors have a higher proportion of integrated systems. The strategy to increase integrated placements will continue.
Q:What is the update on TriageTrue high-sensitivity troponin for point of care?
A:The assay is available outside the U.S. but faces technical challenges for U.S. market approval. The company is working to overcome these hurdles but has no concrete updates for the short term.
Q:What progress has been made in cost-saving and transformation efforts?
A:Initial efforts focused on reducing staffing by 12%. Recent efforts target indirect and direct procurement, with progress in indirect procurement and ongoing work on product cost-related savings. The company continues to challenge all areas of the P&L for cost savings.
Q:Review of Unclear Management Responses
A:Management avoided providing a timeline for the next-generation instrument, citing early concept development. They also did not provide concrete updates on the TriageTrue high-sensitivity troponin assay for the U.S. market, mentioning technical challenges without further details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America donor
BMP testing
CEO afternoon
COVID strength
Conference webcast
Demand VITROS
Diagnostics factor
Diagnostics review
FDA clearance
FDA dialogue
Flu timing
Information Vice
LEX Diagnostics
Labs Demand
Monday test
None dedication
Pacific China
Quidel Financial
QuidelOrtho work
RD affair
RD menu
date
donor screening
focus
geography
hospital
improvement cost
information Investor
menu expansion
momentum
path
sensitivity
testing solution
underpenetration
QDEL Transcript
QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals several concerning factors: negative cash flows, increased inventory levels, and a significant decline in respiratory revenue impacting overall margins. Additionally, the guidance for Q2 is flat, with uncertainties in China affecting revenue. Despite some positive developments in product launches and long-term margin improvements, the immediate outlook remains challenged. Given the company's small-cap status, these negative aspects are likely to result in a stock price decline over the next two weeks.
QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
Unknown2-11
The earnings call provides mixed signals: while revenue and EBITDA guidance are positive, free cash flow fell short due to timing issues. The Q&A reveals sustainable growth in the Lab segment and strategic partnerships, but also highlights uncertainties in respiratory revenue and flat gross margins. The market cap indicates a moderate reaction, leading to a neutral prediction for stock price movement.
QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
Curaleaf Holdings, Inc. (CURA:CA) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents mixed signals. Positive aspects include international growth, improved gross margins, and cash flow generation. However, declines in retail revenue, net loss, and unclear management responses on future margin expansion and regulatory impacts are concerns. The market cap suggests moderate volatility, leading to a neutral stock price prediction.
QDEL Slides
QDEL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
